Oral Paclitaxel Plus Fruquintinib Versus Investigator's Choice in Second-Line Advanced Gastric Cancer
Summary
A Phase III clinical trial (NCT07552402) evaluating oral paclitaxel solution plus fruquintinib versus investigator's choice chemotherapy as second-line therapy in adult subjects with advanced or metastatic gastric or gastroesophageal junction cancer has been registered on ClinicalTrials.gov. The trial will assess both efficacy and safety endpoints. Fruquintinib is a VEGFR inhibitor previously approved for metastatic colorectal cancer. No compliance obligations or regulatory deadlines are associated with this trial registration.
“The goal of this study is to evaluate the efficacy and safety of oral paclitaxel solution plus fruquintinib as second-line therapy in adult subjects with advanced or metastatic gastric (G) or gastroesophageal junction (GEJ) cancer.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
This ClinicalTrials.gov record registers a new interventional Phase III trial (NCT07552402) investigating oral paclitaxel solution combined with fruquintinib as a second-line treatment for adult patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma. The comparator arm uses investigator's choice of standard chemotherapy. No regulatory requirements or compliance obligations are imposed by this registration document.
Healthcare providers and clinical investigators involved in gastric cancer research should note this trial for potential patient referral or competitive landscape awareness. The study represents a novel oral paclitaxel formulation combined with an established VEGFR inhibitor in a late-stage GI malignancy setting.
Archived snapshot
Apr 27, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
N/A NCT07552402 Kind: NA Apr 27, 2026
Abstract
The goal of this study is to evaluate the efficacy and safety of oral paclitaxel solution plus fruquintinib as second-line therapy in adult subjects with advanced or metastatic gastric (G) or gastroesophageal junction (GEJ) cancer.
Conditions: Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Interventions: Oral Paclitaxel Solution Plus Fruquintinib, Investigator Choice (IC) Chemotherapy
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.